Pharmaceuticals 2013, 6(5), 659-680; doi:10.3390/ph6050659

FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver

1email and 2,* email
Received: 28 March 2013; in revised form: 10 April 2013 / Accepted: 24 April 2013 / Published: 29 April 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Many aspects of intercellular communication are mediated through “sending” and “receiving” packets of information via the secretion and subsequent receptor-mediated detection of biomolecular species including cytokines, chemokines, and even metabolites. Recent evidence has now established a new modality of intercellular communication through which biomolecular species are exchanged between cells via extracellular lipid vesicles. A particularly important class of extracellular vesicles is exosomes, which is a term generally applied to biological nanovesicles ~30–200 nm in diameter. Exosomes form through invagination of endosomes to encapsulate cytoplasmic contents, and upon fusion of these multivesicular endosomes to the cell surface, exosomes are released to the extracellular space and transport mRNA, microRNA (miRNA) and proteins between cells. Importantly, exosome-mediated delivery of such cargo molecules results in functional modulation of the recipient cell, and such modulation is sufficiently potent to modulate disease processes in vivo. It is possible that such functional delivery of biomolecules indicates that exosomes utilize native mechanisms (e.g., for internalization and trafficking) that may be harnessed by using exosomes to deliver exogenous RNA for therapeutic applications. A complementary perspective is that understanding the mechanisms of exosome-mediated transport may provide opportunities for “reverse engineering” such mechanisms to improve the performance of synthetic delivery vehicles. In this review, we summarize recent progress in harnessing exosomes for therapeutic RNA delivery, discuss the potential for engineering exosomes to overcome delivery challenges and establish robust technology platforms, and describe both potential challenges and advantages of utilizing exosomes as RNA delivery vehicles.
Keywords: exosome; nanoparticle; siRNA delivery; extracellular vesicle; gene therapy; cancer; immunity
PDF Full-text Download PDF Full-Text [693 KB, uploaded 29 April 2013 10:51 CEST]

Export to BibTeX |

MDPI and ACS Style

Marcus, M.E.; Leonard, J.N. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals 2013, 6, 659-680.

AMA Style

Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals. 2013; 6(5):659-680.

Chicago/Turabian Style

Marcus, Michelle E.; Leonard, Joshua N. 2013. "FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver." Pharmaceuticals 6, no. 5: 659-680.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert